The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib.
H. Safran
No relevant relationships to disclose
K. Charpentier
No relevant relationships to disclose
A. Kaubisch
No relevant relationships to disclose
G. Dubel
No relevant relationships to disclose
G. Soares
No relevant relationships to disclose
K. E. Faricy-Anderson
No relevant relationships to disclose
T. J. Miner
No relevant relationships to disclose
Y. Eng
No relevant relationships to disclose
I. Ribizzi-Akhtar
No relevant relationships to disclose
A. M. Plette
No relevant relationships to disclose
N. J. Espat
No relevant relationships to disclose
D. Berz
No relevant relationships to disclose
A. Schumacher
No relevant relationships to disclose
D. Luppe
No relevant relationships to disclose
P. Bakalarski
No relevant relationships to disclose
P. Wingate
No relevant relationships to disclose
J. Victor
No relevant relationships to disclose
K. Rosati
No relevant relationships to disclose
D. Isdale
No relevant relationships to disclose